Integra Lifesciences Holdings CORP: insider trades · United States · SEC (Form 4)

About Integra Lifesciences Holdings CORP

Integra LifeSciences Holdings Corp. (ticker: IART) is a U.S.-based medical technology company listed on the NASDAQ market in the United States, with headquarters in Princeton, New Jersey. Founded in 1989, the company was originally built around an engineered collagen technology platform designed to repair and regenerate tissue, and it has since broadened into a diversified medtech business serving surgical, neurologic, ENT (ear, nose and throat), and regenerative-care applications. Its customer base is primarily hospitals, surgeons, and specialty-care providers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/917520/000091752025000017/R9.htm?utm_source=openai)) Integra’s business model is centered on a portfolio of complementary products and solutions used across the operating room and adjacent clinical settings. The company markets devices and consumables for neurosurgery, general surgery, tissue reconstruction, wound care, and ENT procedures. This mix gives Integra exposure to multiple end markets while keeping its strategy focused on specialized, higher-value medical technologies rather than commoditized equipment. In practice, that means the company competes on clinical utility, surgeon relationships, product innovation, and regulatory execution, all of which are critical in the medical-device industry. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000917520/000091752025000017/iart-20241231.htm?utm_source=openai)) From a competitive standpoint, Integra sits among specialized medtech suppliers rather than among the largest diversified healthcare conglomerates. Its differentiation lies in depth of indication-specific expertise, a broad surgical portfolio, and the ability to integrate acquisitions and manufacturing capabilities into its product platform. Recent disclosures show the company continuing to focus on portfolio optimization and operational improvements, including plans to relaunch SurgiMend and PriMatrix from a new state-of-the-art manufacturing facility in Braintree, Massachusetts, with operational readiness expected in the first half of 2026. ([sec.gov](https://www.sec.gov/Archives/edgar/data/917520/000091752024000092/ex991-q22024earningsrelease.htm?utm_source=openai)) Recent company updates also highlight ongoing execution efforts and commercial momentum. In its fourth-quarter and full-year 2024 results released in February 2025, Integra reported quarterly revenue growth and described early integration progress from the Acclarent ENT acquisition. For equity investors, the key analytical points are execution risk, manufacturing quality, product relaunch timing, and the company’s ability to translate its specialized portfolio into sustainable organic growth in the U.S. and international markets. As a NASDAQ-listed issuer in the United States, Integra remains a name to watch in the surgical and regenerative-medical device space. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000917520/000091752025000014/ex991q42024earnings.htm?utm_source=openai))